Annika Kim Constantino

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes. 

The White House pulled Weldon's nomination just hours before the former Florida lawmaker was set to appear before the U.S. Senate for confirmation.

Some health policy experts say Kennedy's early moves as HHS Secretary are concerning and suggest that he could undermine immunizations in less direct ways. 

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug. 

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.

AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.

It comes as RFK Jr., a vaccine skeptic who now leads the Department of Health and Human Services, makes moves that could affect vaccination uptake and policy.

Robert F. Kennedy Jr. is making moves that could affect immunization uptake and policy in the U.S., while Oracle submits a formal application to join TEFCA.